Daily Cardiology Research Analysis
Three impactful cardiology studies stand out today: a multicenter AI approach (DeepAC) that improves diagnostic accuracy of SPECT myocardial perfusion imaging without added radiation; a prospective post-market registry (TriCLASP) showing durable clinical benefits of tricuspid transcatheter edge-to-edge repair (T-TEER) with the PASCAL system; and MiCLASP results indicating symptomatic moderate functional MR may benefit from mitral TEER, challenging current guidelines.
Summary
Three impactful cardiology studies stand out today: a multicenter AI approach (DeepAC) that improves diagnostic accuracy of SPECT myocardial perfusion imaging without added radiation; a prospective post-market registry (TriCLASP) showing durable clinical benefits of tricuspid transcatheter edge-to-edge repair (T-TEER) with the PASCAL system; and MiCLASP results indicating symptomatic moderate functional MR may benefit from mitral TEER, challenging current guidelines.
Research Themes
- AI-enhanced cardiovascular imaging and diagnostics
- Transcatheter valve repair outcomes and expansion of indications
- Real-world prospective registries informing practice
Selected Articles
1. General Purpose Deep Learning Attenuation Correction Improves Diagnostic Accuracy of SPECT MPI: A Multicenter Study.
A deep learning model generated synthetic attenuation-corrected SPECT images that improved obstructive CAD prediction versus non–attenuation-corrected images in a large, multicenter external validation. Quantitative scores from DeepAC closely matched CT-based AC, offering a practical pathway to enhance SPECT MPI without extra hardware, time, or radiation.
Impact: Demonstrates a scalable, equipment-free method to improve SPECT diagnostic performance with external, multicenter validation, potentially standardizing care across resource settings.
Clinical Implications: Adoption of DeepAC could reduce false-positive/negative SPECT interpretations, improve CAD triage, and extend AC-like benefits to centers lacking CT-based correction, without added radiation.
Key Findings
- DeepAC improved AUC for obstructive CAD prediction versus non–attenuation-corrected SPECT (0.77 vs 0.73; P < 0.001).
- DeepAC quantitative perfusion scores aligned more closely with CT-based AC than noncorrected images in an independent site cohort.
- Model trained on 4,894 patients and externally validated across 72 sites (n=746) and a second site (n=320), demonstrating broad generalizability.
Methodological Strengths
- Large multicenter training and external validation cohorts
- Head-to-head quantitative comparisons with CT-based AC and NC images
Limitations
- Diagnostic endpoints focused on imaging accuracy rather than prospective clinical outcomes
- Potential variability in SPECT protocols across 72 sites despite standardization
Future Directions: Prospective studies linking DeepAC-based interpretations to downstream management and outcomes, regulatory evaluation, and integration into vendor workflows with explainability tools.
BACKGROUND: Single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) uses computed tomography (CT)-based attenuation correction (AC) to improve diagnostic accuracy. Deep learning (DL) has the potential to generate synthetic AC images, as an alternative to CT-based AC. OBJECTIVES: This study evaluated whether DL-generated synthetic SPECT images could enhance accuracy of conventional SPECT MPI. METHODS: Study investigators developed a DL model in a multicenter cohort of 4,894 patients from 4 sites to generate simulated SPECT AC images (DeepAC). The model was externally validated in 746 patients from 72 sites in a clinical trial (A Phase 3 Multicenter Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD; NCT01347710) and in 320 patients from another external site. In the first external cohort, the study assessed the diagnostic accuracy for obstructive coronary artery disease (CAD)-defined as left main coronary artery stenosis ≥50% or ≥70% in other vessels-for total perfusion deficit (TPD). In the latter, the study completed change analysis and compared quantitative scores for AC, DeepAC, and nonattenuation correction (NC) with clinical scores. RESULTS: In the first external cohort (mean age, 63 ± 9.5 years; 69.0% male), 206 patients (27.6%) had obstructive CAD. The area under the receiver-operating characteristic curve (AUC) of DeepAC TPD (0.77; 95% CI: 0.73-0.81) was higher than the NC TPD (AUC: 0.73; 95% CI: 0.69-0.77; P < 0.001). In the second external cohort, DeepAC quantitative scores had closer agreement with actual AC scores compared with NC. CONCLUSIONS: In a multicenter external cohort, DeepAC improved prediction performance for obstructive CAD. This approach could enhance diagnostic accuracy in facilities using conventional SPECT systems without requiring additional equipment, imaging time, or radiation exposure.
2. Transcatheter mitral repair in patients with symptomatic moderate functional mitral regurgitation: 1-year outcomes from the MiCLASP study.
In this prospective post-market registry, symptomatic moderate FMR (2+) patients undergoing M-TEER with PASCAL achieved sustained MR reduction (≤1+ in ~90% at 1 year) and significant gains in NYHA class and KCCQ, similar to patients with ≥3+ FMR. These findings challenge current guidelines that exclude moderate FMR from M-TEER indications.
Impact: Suggests a potential expansion of M-TEER indications to symptomatic moderate FMR with core-lab echo and adjudicated events, potentially altering patient selection paradigms.
Clinical Implications: For selected symptomatic moderate FMR patients, M-TEER may provide meaningful MR reduction and quality-of-life improvements; multidisciplinary teams should reconsider candidacy on an individualized basis.
Key Findings
- At 1 year, MR ≤1+ was achieved in 89.8% (FMR 2+) and 77.8% (FMR ≥3+) with PASCAL M-TEER (all p<0.001 vs baseline).
- Functional status and QoL improved significantly (NYHA I/II: 67.1% in FMR 2+; KCCQ overall +13.9 points in both groups).
- High survival (90.0% in FMR 2+) and low MAE (13.9%) at 1 year, comparable to ≥3+ FMR group.
Methodological Strengths
- Prospective, multicenter post-market registry with core lab echocardiographic assessment
- Clinical events adjudicated by an independent committee
Limitations
- Single-arm design without randomized comparator limits causal inference
- Potential selection bias in symptomatic moderate FMR referral patterns
Future Directions: Randomized trials comparing M-TEER versus guideline-directed medical therapy in symptomatic moderate FMR to define indications, durability beyond 1 year, and impact on HF hospitalization.
BACKGROUND: Current clinical guidelines do not recommend mitral transcatheter edge-to-edge repair (M-TEER) for patients with moderate functional mitral regurgitation (FMR), and the implications of M-TEER in this population are not well documented. AIMS: We aimed to assess M-TEER outcomes in patients with symptomatic moderate FMR compared to those with FMR ≥3+ who were treated with the PASCAL system in the MiCLASP study. METHODS: Patients were stratified by baseline FMR grade (2+ or ≥3+). The echocardiographic core laboratory-assessed mitral regurgitation (MR) reduction, clinical events committee-adjudicated major adverse events (MAE) rate and functional and quality-of-life outcomes were evaluated up to 1 year after M-TEER. RESULTS: Of the 544 (FMR=322; degenerative MR=163; mixed/other=59) enrolled patients, 101 had baseline FMR 2+ and 197 FMR ≥3+. Both groups achieved significant MR reduction at discharge, which was sustained up to 1 year, with 89.8% of patients achieving MR ≤1+ in the FMR 2+ group and 77.8% in the FMR ≥3+ group (all p<0.001 vs baseline). At 1 year, significant improvements (all p<0.001 vs baseline) in functional capacity (New York Heart Association Class I/II: 67.1% FMR 2+; 70.1% FMR ≥3+) and quality of life (change in the Kansas City Cardiomyopathy Questionnaire overall score: +13.9 points FMR 2+; +13.9 points FMR ≥3+) were achieved in both groups, with high survival (90.0% FMR 2+; 84.2% FMR ≥3+; p=0.176) and low MAE rates (13.9% FMR 2+; 18.3% FMR ≥3+; p=0.413). CONCLUSIONS: In the MiCLASP study, patients with moderate FMR experienced significant MR reduction at 1 year, resulting in clinical and symptomatic benefits comparable to those with ≥moderate-severe FMR, suggesting that select patients with symptomatic moderate FMR can benefit from M-TEER.
3. Transcatheter valve repair of tricuspid regurgitation: 1-year outcomes from the TriCLASP study.
In 300 elderly patients with ≥severe TR, PASCAL T-TEER achieved TR reduction to ≤moderate in 87.7% at 1 year, with low MAE, 88.3% survival, and a 72.2% reduction in annualized HF hospitalizations. Functional status and quality of life improved significantly.
Impact: Provides robust, real-world evidence for safety and effectiveness of T-TEER in severe TR, including clinically meaningful reductions in HF hospitalization and symptomatic improvements.
Clinical Implications: Supports broader adoption of T-TEER for ≥severe TR in high-risk elderly patients, with expectations of reduced HF hospitalizations and improved functional capacity/QoL.
Key Findings
- TR reduced to ≤moderate in 87.7% at 1 year (p<0.001).
- Annualized HF hospitalization rates decreased by 72.2% post-procedure (p<0.001).
- Low MAE (1.7% at 30 days; 12.7% at 1 year) with survival 88.3% and HFH-free survival 83.2%.
Methodological Strengths
- Prospective multicenter post-market study with standardized outcomes
- Comprehensive assessment including TR grade, HF hospitalizations, functional and QoL metrics
Limitations
- Single-arm design without randomized control
- Elderly cohort (mean age ~80) may limit generalizability to younger populations
Future Directions: Head-to-head randomized comparisons of T-TEER versus medical/surgical therapy, long-term durability beyond 1 year, and subgroup analyses by TR etiology and RV function.
BACKGROUND: Patients with tricuspid regurgitation (TR) are at high risk for morbidity and mortality, with poorer outcomes associated with increasing TR severity. Tricuspid transcatheter edge-to-edge repair (T-TEER) has emerged as a promising treatment option. AIMS: TriCLASP is a prospective, single-arm, European post-market study evaluating the safety and effectiveness of T-TEER with the PASCAL system to treat patients with ≥severe TR. METHODS: The TriCLASP study enrolled 300 patients to evaluate the safety and performance of T-TEER. Major adverse events (MAE), reduction in TR grade, and clinical, functional, and quality-of-life outcomes were assessed at 1 year. RESULTS: Enrolled patients had a mean age of 80.1 years, 52.0% were female, and 75.8% had ≥severe TR. Tricuspid regurgitation was reduced to ≤moderate in 87.7% of patients (p<0.001). The composite MAE rate was 1.7% at 30 days and 12.7% at 1 year. Kaplan-Meier estimates for survival and freedom from heart failure hospitalisation (HFH) were 88.3±1.9% and 83.2±2.3%, respectively. Annualised HFH rates decreased by 72.2% in the 12 months pre- versus post-procedure (p<0.001). Significant functional and quality-of-life improvements were observed from baseline to 1 year, including 74.5% of patients in New York Heart Association Class I/II, a 29.4-metre increase in the 6-minute walk distance, and an 8.3-point increase in the Kansas City Cardiomyopathy Questionnaire score (p<0.001). CONCLUSIONS: The 1-year results of the TriCLASP study confirm the safety and effectiveness of T-TEER with the PASCAL system in patients with ≥severe TR. Patients experienced significant TR reduction, low mortality, high freedom from HFH, and significant improvements in symptoms, functional capacity, and quality of life.